Manufacture of basic pharmaceutical products (PKD 21.10.Z)
This subclass includes:
- the production of active pharmaceutical ingredients used in the manufacture of pharmaceutical products (for example antibiotics, basic vitamins, salicylic acid, aspirin),
- blood processing,
- the production of chemically pure sugars,
- the production of probiotics,
- gland processing,
- the production of gland extracts.
This subclass excludes:
- the production of pharmaceutical products for advanced cell and gene therapy, classified in 21.20.Z.
Industry statistics (2025)
Number of companies
Companies
Business turnover
Legal structure
Legal formShare of companiesNumber of companies
- Sp. z o.o.79.8%134
- Sp. j.11.3%19
- S.A.3.6%6
- Sp. k.1.8%3
- JDG1.2%2
- P.S.A.1.2%2
- Other0.6%1
Financial results
Median revenue
Ranking
Median revenue compared with other PKD codes.
Top companies by revenue
| # | Company | Legal form | Revenue | Net profit |
|---|---|---|---|---|
| 1 | sp. z o.o. | USD 101.19m | USD 5.85m | |
| 2 | sp. z o.o. | USD 8.23m | USD 1.77m | |
| 3 | sp. z o.o. | USD 7.35m | USD 2.38m | |
| 4 | sp. z o.o. | USD 5.51m | USD 662.57k | |
| 5 | S.A. | USD 4.69m | USD 873.80k | |
| 6 | sp. j. | USD 4.14m | USD 141.39k | |
| 7 | sp. z o.o. | USD 2.24m | USD 98.73k | |
| 8 | sp. z o.o. | USD 2.19m | USD -1.86m | |
| 9 | sp. z o.o. | USD 2.04m | USD 8.52k | |
| 10 | sp. z o.o. | USD 1.97m | USD 134.27k |
Fastest-growing companies
| # | Company | Legal form | Revenue | Y/Y growth |
|---|---|---|---|---|
| 1 | sp. z o.o. | USD 1.80m | +530.7% y/y | |
| 2 | sp. z o.o. | USD 101.19m | +333.1% y/y | |
| 3 | sp. z o.o. | USD 7.35m | +80.7% y/y | |
| 4 | sp. z o.o. | USD 1.97m | +50.5% y/y | |
| 5 | sp. z o.o. | USD 757.63k | +36.8% y/y | |
| 6 | sp. z o.o. | USD 906.74k | +14.8% y/y | |
| 7 | sp. z o.o. | USD 1.03m | +14.1% y/y | |
| 8 | sp. z o.o. | USD 1.71m | +13.0% y/y | |
| 9 | sp. j. | USD 4.14m | +10.4% y/y | |
| 10 | sp. z o.o. | USD 414.89k | +8.8% y/y |
Stock market
No companies from this industry are listed.
Related PKD codes in division 21
FAQ
The primary industry for 168 companies is manufacture of basic pharmaceutical products. 69 entities have filed financial statements.
So far in 2026, 4 new companies with PKD 21.10.Z have been registered. In all of 2025, there were 6 such companies.
In 2025, the median revenue for PKD 21.10.Z was USD 172.76k and the mean revenue was USD 3.09m, based on 50 financial statements. Averages and medians include only companies that file financial statements, excluding sole proprietorships.
Yes, in 2025, the median net profit was USD 7.40k, an improvement on 2024 (USD 4.02k). Among all 628 industries in Poland, PKD 21.10.Z ranks 469th, placing it among the weakest 25%.
The most common legal form for PKD 21.10.Z is sp. z o.o., used by 134 companies in this industry (79.8% of the total). In second place is sp. j. (19 companies, 11.3%), and in third place – S.A. (6 companies, 3.6%).




